BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 22, 2013
 |  BioCentury  |  Emerging Company Profile

Cardiorentis: Keeping heart

Cardiorentis believes fifth time's the charm for ularitide to treat heart failure

Cardiorentis AG is the fifth company to take on development of ularitide for acute heart failure. Armed with more than €100 million ($129.9 million) from undisclosed investors and expecting to have to do a smaller Phase III program than EMA wanted from ularitide's previous sponsor, Cardiorentis hopes to show the compound can both control symptoms and improve mortality.

"Ularitide went through a few hands and unfortunately did not get developed or get the attention it deserved," Chairman and CEO Elmar Schnee told BioCentury.

PDL BioPharma Inc. gained the program through its 2005 acquisition of ESP Pharma Inc., which had in-licensed the program from CardioPep Pharma GmbH.

Despite reporting positive data from the Phase II SIRIUS II trial, PDL put Phase III plans on hold in 2006 after EMA requested a program more than three times larger than the company had expected. The agency requested two trials in a total of 3,300 patients (see BioCentury, Jan. 22, 2007).

Ularitide is a synthesized form of the naturally occurring natriuretic peptide urodilatin. Data published in the European Heart...

Read the full 876 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >